XM, Amerika Birleşik Devletleri'nde ikamet edenlere hizmet sunmamaktadır.
F
F

Fresenius


Haberler

Fresenius SE: Announces EMA Acceptance For Review Of Denosumab Biosimilar Candidates

BRIEF-Fresenius SE: Announces EMA Acceptance For Review Of Denosumab Biosimilar Candidates July 11 (Reuters) - Fresenius SE & Co KGaA FREG.DE : ANNOUNCES EMA ACCEPTANCE FOR REVIEW OF DENOSUMAB BIOSIMILAR CANDIDATES Further company coverage: FREG.DE Reporting by Berlin Newsroom
F

Banco Bpm, Firstgroup, Xps Pensions

EUROPE RESEARCH ROUNDUP-Banco Bpm, Firstgroup, Xps Pensions June 11 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Banco Bpm, Firstgroup and Xps Pensions Group, on Tuesday. HIGHLIGHTS * Banco Bpm BAMI.MI : Morgan Stanley cuts to equal weight from overweight * Firstgroup Plc FGP.L : RBC raises target price to 200p from 195p * JCDecaux SE JCDX.PA : Deutsche Bank cuts to hold from buy * Next Plc NXT.L : HSBC raises target price to 9,
B
B
C
C
D
E
E
E
E
F
H
H
H
I
K
M
N
N
S
S
U
U
H
A
B
I

Ashtead Technology Holdings, Computacenter, Maersk

EUROPE RESEARCH ROUNDUP-Ashtead Technology Holdings, Computacenter, Maersk June 6 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Ashtead Technology Holdings, Computacenter and Maersk on Thursday. HIGHLIGHTS * Ashtead Technology Holdings Plc ATAS.L : Stifel raises target price to 900p from 770p * Computacenter Plc CCC.L : Morgan Stanley cuts target price to 2550p from 2650p * IG Group Holdings Plc IGG.L : Deutsche Bank cuts target
B
E
F
G
I
I
I
K
R
R
S
V
W
A
A
B
M

Fresenius lifts 2024 targets for private healthcare unit Helios

Fresenius lifts 2024 targets for private healthcare unit Helios June 5 (Reuters) - German healthcare group Fresenius FREG.DE raised the yearly guidance for its private healthcare provider Helios on Wednesday, following a strong start to 2024 and the conclusion of group-wide restructuring. The Hessian-based group expects Helios to grow its revenue by a mid-single-digit percentage and report an earnings before interests and taxes (EBIT) margin of 10% to 11% this year.
F
F

Top of the Street: Fresenius, Freenet, European tyremakers

BUZZ-Top of the Street: Fresenius, Freenet, European tyremakers A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** UBS upgrades mobile retailer and service provider Freenet FNTGn.DE to "buy" from "hold", saying it benefits from competitive tensions in the German mobile market that have pushed operators to give it longer term deals ** HSBC raises German healthcare group Fresenius FREG.DE to "buy" from "hold" and increases its TP by 23% to 38 euros INITIATION
C
F
F
H
F

Allianz, Carnival, Future

EUROPE RESEARCH ROUNDUP-Allianz, Carnival, Future June 4 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Allianz, Carnival and Future, on Tuesday. HIGHLIGHTS * Allianz SE ALVG.DE : Citigroup cuts to neutral from buy * Carnival CCL.L : Peel Hunt raises to buy from add * Future Plc FUTR.L : Berenberg raises to buy from hold * Liontrust Asset Management Plc LIO.L : Deutsche Bank cuts to sell from hold * Nibe NIBEB.ST : Barclays cuts t
A
A
C
D
F
F
H
I
I
K
L
L
M
N
P
R
A
A
A
B
F
P
Z

Fresenius - Sang-Jin Pak Takes Over Management Of Biopharma At Fresenius Kabi

BRIEF-Fresenius - Sang-Jin Pak Takes Over Management Of Biopharma At Fresenius Kabi May 29 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : DR. SANG-JIN PAK TAKES OVER THE MANAGEMENT OF THE BIOPHARMA BUSINESS AT FRESENIUS KABI WITH EFFECT FROM JUNE 1, 2024 MICHAEL SCHÖNHOFEN, HEAD OF BIOPHARMA AND MEMBER OF THE FRESENIUS KABI MANAGEMENT BOARD, LEAVES
F

Fresenius Says FDA Accepts For Review Denosumab Biosimilar Application

BRIEF-Fresenius Says FDA Accepts For Review Denosumab Biosimilar Application May 27 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF DENOSUMAB BIOSIMILAR APPLICATION Further company coverage: FREG.DE (Gdansk Newsroom)
F

FLSmidth, Neste, Sonova Holding

EUROPE RESEARCH ROUNDUP- FLSmidth, Neste, Sonova Holding May 20 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including FLSmidth, Neste and Sonova Holding, on Monday. HIGHLIGHTS * FLSmidth FLS.CO : JP Morgan raises target price to DKK 400 from DKK 310 * IMCD NV IMCD.AS : JP Morgan cuts target price to EUR 185 from EUR 188 * Neste Oyj NESTE.HE : Stifel cuts target price to EUR 37 from EUR 40 * Sonova Holding AG SOON.S : Morgan Stanley cuts
B
C
C
E
E
E
F
F
G
N
P
R
S
S
S
S
T
U
U
V
A
F
R

Investors demand clarity from Fresenius over dialysis group FMC

Investors demand clarity from Fresenius over dialysis group FMC FRANKFURT, May 17 (Reuters) - Investors demanded more clarity from German healthcare group Fresenius SE FREG.DE on Friday regarding its plans to cede strategic control over dialysis group Fresenius Medical Care FMEG.DE . "The volatility at Fresenius Medical Care seems to repeatedly overshadow the recent positive operating developments at Fresenius and is also deterring many potential shareholders from investing in Fresenius," said H
F
F

Alfa Laval, OMV AG, Unilever Plc

EUROPE RESEARCH ROUNDUP- Alfa Laval, OMV AG, Unilever Plc May 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alfa Laval, OMV AG and Unilever Plc, on Tuesday. HIGHLIGHTS * Alfa Laval ALFA.ST : JP Morgan raises target price to SEK 385 from SEK 325 * Babcock International BAB.L : Citigroup raises target price to 640p from 530p * OMV AG OMVV.VI : Morgan Stanley raises to equal weight from underweight * SKAN Group AG SKAN.S : Baader
A
A
A
B
C
C
D
F
G
H
I
I
I
L
M
O
O
P
S
S
S
T
A
B
B
D
J
P

Coloplast, National Grid, Smurfit Kappa

EUROPE RESEARCH ROUNDUP- Coloplast, National Grid, Smurfit Kappa May 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Coloplast, National Grid and Smurfit Kappa, on Monday. HIGHLIGHTS * AFC Ajax NV AJAX.AS : Berenberg cuts to hold from buy; cuts PT to EUR 11 from EUR 17 * Coloplast COLOB.CO : HSBC raises target price to DKK 710 from DKK 700 * JD Wetherspoon JDW.L : HSBC raises target price to 1030p from 1020p * National Grid NG.L
A
E
F
M
M
R
U
A
B
B
B
B
E
F
I
J
N
S

Fresenius Q1 Group EBITDA Before Special Items Up 13% At EUR 924 Mln

BRIEF-Fresenius Q1 Group EBITDA Before Special Items Up 13% At EUR 924 Mln May 8 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : Q1 GROUP REVENUE UP 4% AT EUR 5.7 BILLION Q1 GROUP EBITDA BEFORE SPECIAL ITEMS UP 13% AT EUR 924 MILLION Q1 GROUP NET INCOME BEFORE SPECIAL ITEMS UP 10% AT EUR 429 MILLION Q1 GROUP EBIT BEFORE SPECIAL ITEMS UP 15% AT EUR 633
F

Fresenius Q1 beat, outlook hike boosts shares

BUZZ-Fresenius Q1 beat, outlook hike boosts shares ** Fresenius's FREG.DE stock rises around 3% in early Frankfurt trade after the German healthcare group raised its full-year outlook and reported better-than-expected Q1 results ** It now expects its organic group revenue to grow by 4%-7% this year, up from a previously expected 3%-6% ** First-quar
F
G

Fresenius marks restructuring end with Vamed exit, raises outlook

UPDATE 3-Fresenius marks restructuring end with Vamed exit, raises outlook Adds detail on Vamed exit in paragraphs 1-3, CEO quote in paragraph 4, analyst comment in paragraph 6 By Tristan Veyet May 8 (Reuters) - Germany's Fresenius FREG.DE said on Wednesday it had completed its restructuring with a "structured exit" from its loss-making service unit Vamed as it raised its outlook for 2024 after beating first-quarter forecasts.
F
F

Fresenius SE: Fresenius Exits Its Investment Company Vamed

BRIEF-Fresenius SE: Fresenius Exits Its Investment Company Vamed May 8 (Reuters) - Fresenius Se FREG.DE : FRESENIUS EXITS ITS INVESTMENT COMPANY VAMED VAMED’S OPERATIONS IN AUSTRIA TO BE SOLD TO AN AUSTRIAN CONSORTIUM OF CONSTRUCTION COMPANIES, PORR AND STRABAG VAMED’S HOSPITAL SERVICES UNIT TO BE TRANSFERRED TO THE FRESENIUS GROUP VAMED'S INTE
F

German healthcare group Fresenius Q1 EBIT beats expectations

German healthcare group Fresenius Q1 EBIT beats expectations May 7 (Reuters) - German healthcare group Fresenius FREG.DE first quarter results beat expectations, the company said on Wednesday, citing strong performance at its operating companies. First-quarter earnings before interests and taxes (EBIT) were 633 million euros ($679.78 million). That was above investors' expectation of 606 million euros, according to a consensus of forecasts from Vara research.
F
F

Fresenius Raises Outlook For Fiscal Year 2024

BRIEF-Fresenius Raises Outlook For Fiscal Year 2024 May 7 (Reuters) - Fresenius SE & Co KGaA FREG.DE : EQS-ADHOC: FRESENIUS SE & CO. KGAA: FRESENIUS RAISES OUTLOOK FOR FISCAL YEAR 2024 FRESENIUS NOW EXPECTS ORGANIC GROUP REVENUE GROWTH BETWEEN 4 AND 7% FOR FISCAL YEAR 2024 (PREVIOUSLY: 3 TO 6%) FY EBIT MARGIN IS NOW EXPECTED TO RANGE BETWEEN 15 AND
F

Germany corporate earnings week ahead

DIARY-Germany corporate earnings week ahead May 3 (Reuters) - Diary of Germany (.GDAXI) corporate earnings for the week ahead GERMANY EARNINGS Start Date Start Time(GMT) RIC Company Name Event Name 07-May-2024 NTS IFXGn.DE Infineon Technologies AG Q2 2024 Infineon Technologies AG Earnings Release 07-May-2024 NTS SHLG.DE Siemens Healthineers AG Q2 2024 Siemens Healthineers AG Earnings Release 07-May-2024 05:00 DHLn.DE Deutsche Post AG Q1 2024 Deutsche Post AG Earnings Release 07-May-2024 05:00 ZA
B
C
F
H
I
S
Z
G

Fresenius To Divest Vamed's Rehabilitation Business

BRIEF-Fresenius To Divest Vamed's Rehabilitation Business May 2 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : DIVESTS VAMED'S REHABILITATION BUSINESS PAI PARTNERS ("PAI") TO ACQUIRE CONTROLLING MAJORITY OF 67 PERCENT, FRESENIUS TO RETAIN 33 PERCENT TO PARTICIPATE IN FUTURE UPSIDES CLOSING EXPECTED IN SECOND HALF OF YEAR Further company coverage: FRE
F



Şartlar

Popüler varlıklar

Bildirim: XM Group şirketlerinin her biri yalnızca gerçekleştirme hizmeti ve online yatırım platformumuza erişim sağlar. Herhangi bir kişinin web sitesinde bulunan veya web sitesi üzerinden sağlanan içeriği görüntülemesine ve/veya kullanmasına izin vermek, bu hizmeti değiştirmek veya genişletmek amaçlı değildir ve bu hizmeti ne değiştirir ne de genişletir. Bu tür erişim ve kullanım her zaman şunlara tabidir: (i) Şartlar ve Koşullar; (ii) Risk Uyarıları ve (iii) Tam Bildirim. Bu nedenle bu tür içerikler yalnızca genel bilgi amacıyla sağlanır. Özellikle, online yatırım platformumuzun içeriklerinin finans piyasalarında herhangi bir işleme girmek için bir teşvik veya bir teklif olmadığını lütfen dikkate alın. Herhangi bir finans piyasasında yatırım yapmak sermayeniz için önemli düzeyde risk taşır.

Online yatırım platformumuzda yayınlanan tüm materyaller yalnızca eğitim/bilgilendirme amaçlıdır ve finansal tavsiye, yatırım vergisi veya yatırım tavsiyesi ve önerileri ya da yatırım fiyatlarımızın kaydı veya herhangi bir finansal enstrümanda işlem yapılması için bir teklif veya teşvik ya da talep edilmemiş finansal promosyonları içermez ve içerdiği şeklinde bir değerlendirme yapılmamalıdır.

Görüşler, haberler, araştırma, analizler, fiyatlar, diğer bilgiler veya bu web sitesinde bulunan üçüncü taraf sitelere verilen bağlantılar gibi her türlü üçüncü taraf içeriğin yanı sıra XM tarafından hazırlanan içerik de “olduğu gibi” esasına göre, genel piyasa yorumu olarak sağlanır ve bir yatırım tavsiyesi oluşturmaz. Herhangi bir içeriğin yatırım araştırması olarak yorumlanmasıyla ilgili olarak, içeriğin bağımsız yatırım araştırmasını desteklemek üzere tasarlanmış yasal gerekliliklere uygun hazırlanmadığını ve bu amacın güdülmediğini, aynı şekilde ilgili yasalar ve mevzuatlar kapsamında pazarlama iletişimi olarak değerlendirileceğini dikkate almalı ve kabul etmelisiniz. Buradan erişebileceğiniz Bağımsız Olmayan Yatırım Araştırması Bildirimimizi ve yukarıdaki bilgilerle ilgili Risk Uyarımızı okuduğunuzdan ve anladığınızdan emin olun.

Risk uyarısı: Sermayeniz risk altında. Kaldıraçlı ürünler herkese uygun olmayabilir. Lütfen Risk Bildirimi'mizi dikkate alın.